The following lists some of the more popular stocks – not in any order of ranking – traded by POEMS customers amidst with major stock announcements in the month of September.
At a glance:
- After a long rally, the three major indices closed lower in September..
- Market sell-offs were a result of poor job market report, the Evergrande debt issue and a potential Government shutdown.
- The Federal Reserve announced that tapering might start soon without any rate hikes this year.
Traditionally, September is a bad month for Equities, possibly due the quadruple witching event where stock index futures, stock index options, stock options, and single stock futures expire simultaneously1.
The three US major indices – Dow Jones, S&P 500 and Nasdaq Composite opened the month on a positive note with hopes on China Stimulus2. The hope came about when Chinese manufacturing activities slowed for the first time since April 20203. This spurred investors to speculate that the Chinese government might have plans to implement fiscal policies to boost growth.
Subsequently, the three indices dipped following the disappointing results in August’s job report4. Economists were expecting a payroll increase of 720,000 in August. However, the market was greeted with an increase of 235,000 instead. This signalled that the economy was not recovering at the expected pace; the COVID-19 pandemic remains the limiting factor.
Shortly after, the Evergrande debt issue emerged due to a liquidity crunch. Evergrande is one of the largest real estate developers in the world. It is also however, the most indebted of them all. The Evergrande liquidity crunch came about from Beijing’s tightening of property developers’ borrowings5. Evergrande has an offshore debt of US$20 Billion and has missed two of its bond coupon payments.
Subsequently, Jerome Powell announced after the Federal Open Market Committee (FOMC) that tapering “may soon be warranted” and interest rate hikes will not be happening this year. This announcement put the market at ease but soon faced the uncertainty of the US government shutting down. A shutdown typically occurs when politicians fail to agree on a budget. When the government shuts down, debts that are deemed as risk-free will be defaulted which could be devastating on a global level6. Despite a few occurrences of the US government shutting down in the past, there were no instances of them defaulting on the loans.
Overall, the 3 major US indices ended the month on a negative note.
Tilray Inc (NASDAQ: TLRY)
Tilray Inc (TLRY) traded downwards for this month. They opened at US$13.74 and closed for the month at US$10.95, representing a loss in value of 21.3%.
The future looks bright for TLRY as the Federal Marijuana Legalization Bill clears with the House Committee7. With democrats controlling the Presidency and both chambers of congress, passing a bill that democrats favour will be easier.
This blue wave worked well for TLRY as all democrats supported the bill, suggesting that democrats may be in favour of legalising Marijuana at the Federal level. With that being said, trying to gain a piece of the US$17 Bil8 market in the US may prove challenging. TLRY will have to take the domestic US operators into consideration as they may have a strong foothold in the country, having instilled brand loyalty in US consumers. Thus, TLRY may need to invest in differentiating itself from its competitors.
TLRY released its quarter ending August 2021 results on 7 October 2021. The reported EPS for the same quarter last year was US$-0.27 which is lower than the current quarters of US$-0.08. Despite the improvement from last year, the latest quarter EPS was worse than the consensus EPS of US$-0.06. Moving forward, TLRY has plans to work in new product categories like wine in cans9.
Status: Bearish momentum
Immediate resistance must be broken for more upside
BIONANO GENOMICS (NASDAQ: BNGO)
BIONANO GENOMICS (BNGO) analyses long segments of DNA, detecting genetic diseases. BNGO traded downwards for this month, opening at US$5.79 and closed at US$5.50 which is a loss of 5%.
BNGO did a few gene research, including the largest clinical research for muscle weakness10 and scientific study on biomarkers for Lung Cancer11. Additionally, they were recently added into the Russell 2000 list which is closely followed by investors worldwide to measure the overall performance of small-cap to mid-cap stocks. This will add trading volume to the stock as funds that follow the index will need to mimic the index composition.
The latest revenue figure for Q2 2021 was US$3.9 million which is 229% higher than Q2 of 202012. Their current gross margin is at 37% with expectations for gross margins to remain. For EPS, they reported US$-0.06 which was lower than the estimated US$-0.05. Their goal for 2021 is to install 150 units of Saphyr, an optical genome mapping instrument. They have installed 121 units of such systems as of 30 June this year and are confident of hitting their goal.
Earnings for 3Q21 will be released on 11 November 2021 and the EPS forecast is at -0.0613.
Moderna Inc (NASDAQ: MRNA)
September has been a volatile month for Moderna Inc (MRNA). MRNA started off the month at US$382.84 and climbed 21% to a high of US$464.12 before closing the month flat at US$384.86.
The movement for the month was mainly due to a few factors.
MRNA’s announcement to develop a two-in-one vaccine for COVID-19 and Flu14 caused MRNA to rally. The newly developed vaccine provides a booster against both COVID-19 and flu with a single dose. Phase 2/3 of the study is planned to launch by the end of 2021.
The second rally rooted from the possibility of having booster shots15. Given that millions may need Booster shots, this could potentially boost MRNA’s revenue considerably. However, accurate estimation of the volume of booster shots required remains unknown in this equation.
The downward pressure resulted from Food and Drug Administration (FDA)’s support for the booster shots to be administered only to those aged 65 and above. This information came as a blow to the vaccine maker as investors were expecting a wider range of individuals needing the booster jab. The FDA panel voted against booster shots for those under the age of 65, hence limiting the demand for booster shots severely.
Lucid Group Inc (NASDAQ: LCID)
Lucid Group Inc (LCID), formerly known as Atieva, was founded in 2007 as an American electric vehicle manufacturer.
LCID announced that production of its US$169,000 Air Dream Edition luxury sedan has begun from 28 September 2021. They also announced cashless redemption of its public warrants. Furthermore, the US Environmental Protection Agency officially gave LCID a record 520-mile battery range rating. The above-mentioned factors contributed to the bullishness on LCID stock, which saw shares of LCID soar 27.2%.
LCID delivered 577 units of its first and newly launched Lucid Air in 2021. They are aiming to deliver a further 20,000 units in 2022.
The company mentioned that it has received more than 13,000 reservations for Lucid Air models as of September 2021.
The share price of LCID is currently trading towards a high for the month at US$24.01 as at 20 September 2021. The highest in the month was traded at US$27.85 and the lowest was traded at US$18.93.
Immediate resistance must be broken for more upside
TESLA INC (NASDAQ: TSLA)
Tesla Inc (TSLA), the maker of electric vehicles with the largest market cap in the auto industry, continued its winning streak from last quarter when it surpassed the 200,000-car delivery figure for the first time since it began reporting earnings. Pandemic-induced supply chain bottlenecks and global chip shortages slowed operations in the automobile industry as a whole. Hence, it is extremely impressive that TSLA managed to thrive even in such harsh environments.
TSLA produced a total of 237,823 vehicles in the third quarter of 202116, nearly 3.6% more than anticipated. Out of that figure, 228,882 vehicles were Model 3 or Model Y cars—its mid-range cars targeted at price-conscious customers. The company also produced 8,941 editions of its pricier best-seller sedans Model S and Model X.
With tailwinds from the Biden administration through the legislation to make electric cars cheaper and announcements of further plans to build infrastructure to support electric vehicles, TSLA is positioned to benefit even through this pandemic-laden period.
The increase in prices for important materials essential to the auto industry, like steel and aluminium, will see a massive cost increase, Tesla is experiencing an inventory shortage causing its car prices to rise as a result.
TSLA has been on a bullish run for 7 consecutive weeks since August 2021. It’s share price is trading towards a high for the month at US$782.75, the highest in the month was traded at US$806.97 and the lowest was traded at US$712.73.
Status: Bullish Momentum
Immediate resistance will turn support once broken once bullish candle close
Ideanomics Inc (NASDAQ: IDEX)
Ideanomics Inc (IDEX) provides opportunities for investors in the financial technology (fintech) and electric vehicle(EV) industries. The company aims to manufacture zero-emission commercial vehicles like trucks and buses, and provide wireless charging17.
In the month of September, IDEX announced that they will be further supporting Energica Motor by employing their Capital and Mobility divisions18. This partnership will create a new Dealer Floor Plan financing arrangement that will help to double the number of in house EV car dealers in the United States. IDEX deems that this collaboration can help with scaling and growing their revenue and also increase brand awareness among consumers.
Thus, with IDEX taking steps to gain market share in the EV industry, the current dip in price may be a good buy for investors. IDEX closed 20.8% lower for September, from the opening price of US$2.49 to a closing of US$1.9719.
Nio Inc (NYSE: NIO)
Nio Inc (NIO), a major player in the electric vehicle (EV) industry reported their monthly quarterly deliveries for Q3. Results showed that NIO delivered 10628 vehicles globally in September 2021, which is about an 80% increase from August 5880 deliveries and is also the highest number of deliveries that Nio has completed. There was a total of 24,439 vehicles delivered in Q3, beating estimates of 22,500 to 23,500 by about 6% and an increase in deliveries by 11.6% compared to the previous quarter of 21,896.
NIO has also announced that they have completed delivery of their first batch of vehicles to Norway, opening the doors for them to compete for market shares in the Europe market. With continuous increase in deliveries that lead to an increase in revenue, analysts believe that NIO might turn into a profit by 2023. As of September closing, NIO is trading at US$35.63, which is about a 5% drop from the opening of US$37.49.
Status: Bullish Momentum
Immediate support has to hold for more upside
Xpeng Inc (NYSE: XPEV)
Dropping from a month opening at US$41.10 to close at US$35.54 (13.5% drop), Xpeng Inc (XPEV); another major player in the Electric Vehicle (EV) industry appealing to a large growing base of technology-savvy middle-class consumers in China, announced vehicle delivery results for September and Q3 2021. There was a total of 10,412 deliveries made in September a record high, 44.3% higher than the previous month of 7,214. This brings the total deliveries made for Q3 to 25,666 vehicles.
In the month of September, XPEV also launched P5, their new model with lidar sensors. These sensors distinguish pedestrians, cyclists and other objects in different locations and weather. With the advancement of technology, self-driving might become a norm. The continuous increase in deliveries as well as the newly launched model could potentially attract consumers who appreciate technology with unique features.
Status: Bullish Momentum
Immediate support has to hold for more upside
Palantir Technologies Inc (NYSE: PLTR)
Palantir Technologies Inc (PLTR), a software company that provides enterprise data platforms that are mainly used by organisations with complex and sensitive data, closed at US$24.04 for the month of September, a 9.15% drop from its opening price of US$26.46. PLTR announced that they have been selected by the US Army for intelligence Systems and Analytics to deliver intelligence data and analytics foundation. PLTR was also selected for the US Army’s US$823 million indefinite delivery and quantity contract.
While this sheds some light on their revenue levels, it also signifies the capabilities and trustworthiness of PLTR’s branding for big data analytics. The collaboration between PLTR and the US Army serves as a good springboard for the company to leverage, attracting potential collaborations with other corporate enterprises.
Apple Inc (NASDAQ: AAPL)
Closing at US$141.50 for the month of September, a 7.4% drop from an opening of US$152.83, Apple Inc (AAPL) launched their new iPhone model, iPhone 13 Pro. The new iPhone model offers a number of new features that should catch the attention of consumers. The latest A15 Bionic processor operates 50% faster than its competitors’ phone models. As consumers continue to seek for newer and faster technology, the new iPhone could potentially catch the attention from both new and existing users.
According to survey results, 65% of current iPhone users are looking to upgrade their mobiles, while around 50% of Android users have the desire to make the switch over to iOS. Additionally, 54% of respondents showed interest in the iPhone 13 Pro model. The evidently high demand for the new iPhone 13 model could potentially boost revenues for AAPL. However, supply chain blockages might result in delays in deliveries, hence a slower revenue is expected.
Immediate resistance must be broken for more upside
Bloomberg analysts’ recommendations
The table below shows the consensus ratings and average ratings of all analysts updated on Bloomberg in the last 12 months. Consensus ratings have been computed by standardising analysts’ ratings to a scale of 1 (Strong Sell) to 5 (Strong Buy). The table also shows the number of analysts’ recommendations to buy, hold or sell the stocks as well as their average target prices.
||Target Price (US$)
|Ideanomics Inc (NASDAQ: IDEX)
|BIONANO GENOMICS (NASDAQ: BNGO)
|Xpeng Inc (NYSE: XPEV)
|Nio Inc (NYSE: NIO)
|Apple Inc (NASDAQ: AAPL)
|Lucid Group Inc (NASDAQ: LCID)
|TESLA INC (NASDAQ: TSLA)
|Tilray Inc (NASDAQ: TLRY)
|Moderna Inc (NASDAQ: MRNA)
|Palantir Technologies Inc (NYSE: PLTR)
To round up
September was a volatile month with many unforeseen events. Majority of the stocks had a lower month closing and hence might be a good opportunity for investors to pick up stocks with good potential at a discounted price. Despite the setbacks faced in September, the Bloomberg analysts are still bullish in the near term. Based on the latest FOMC, tapering is expected to take place by year end and the first-rate hike is expected in 2022 which could lift some uncertainty off the market.
Click here to learn more about trading stocks in the US
Click here to open a POEMS trading account
Important Information: This report is prepared and/or distributed by Phillip Securities Research Pte Ltd (“Phillip Securities Research”), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgement. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSES Where the report contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.
If Distribution is to Australian Investors This report is produced by Phillip Securities Pte Ltd and is being distributed in Australia by Phillip Capital Limited (Australian Financial Services License No. 246827). This report contains general securities advice and does not take into account your personal objectives, situation and needs. Past performance is not a reliable indicator of future performance. Please read the Disclosures and Disclaimers set out above. By receiving or reading this report, you agree to be bound by the terms and limitations set out above. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately